Bone marrow uptake of indolent non-Hodgkin lymphoma on PET/CT with histopathological correlation by Khong, PL et al.
Title Bone marrow uptake of indolent non-Hodgkin lymphoma onPET/CT with histopathological correlation
Author(s) Lee, EYP; Singh, GHH; Wang, Y; Kwong, YL; Khong, PL




This is a non-final version of an article published in final form in
Nuclear Medicine Communications, 2015, v. 36 n. 10, p. 1035-









To evaluate the diagnostic accuracy of PET/CT in detecting marrow infiltration in 
indolent non-Hodgkin lymphoma(NHL) with histopathological correlation. 
Methods  
All treatment-naive newly diagnosed indolent NHL with staging PET/CT were 
retrospectively evaluated for marrow infiltration and categorized based on PET/CT 
uptake pattern: normal (PET/CT negative, -ve), focal/diffuse (PET/CT positive, +ve). 
Bone marrow biopsy (BMB)was taken as the standard except in focal PET/CT uptake, 
which was confirmed to be positive or negative by serial PET/CT. BMB pattern was 
assessed as diffuse and non-diffuse, and degree of lymphoid infiltration documented. 
Results 
Forty-six patients (mean age 59±15 years) were evaluated. In the PET/CT +ve group 
of 22 cases (diffuse=15, focal=7), BMB was positive in 21 cases. In 80% of diffuse 
PET/CT uptake cases, a diffuse BMB infiltrative pattern was observed. However, in 
cases with focal PET/CT uptake, no predominant histological pattern was observed. 
No correlation was found between semi-quantitative uptake and degree of lymphoid 
infiltration on BMB (r=0.2, p=0.434). In the PET/CT –ve group of 24 cases, 20 cases 
were BMB negative and 4 cases were positive. The overall diagnostic accuracy of 
PET/CT in determining marrow infiltration was 89% (sensitivity 84%, specificity 
95%, positive predictive value 95% and negative predictive value 83%). 
Conclusion 
PET/CT showed high specificity and positive predictive value with moderate 
accuracy in detecting marrow disease in indolent NHL. The metabolic uptake lacked 
significant correlation with the degree of lymphoid infiltration but a potential 
relationship may exist between pattern of metabolic uptake and BMB infiltrative 
pattern.     
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Introduction 
Bone marrow (BM) infiltration in lymphoma upstages the disease based on the Ann 
Arbor staging system. In prognostic models for both aggressive and indolent 
lymphomas, BM infiltration is a significant negative predictor of disease outcome [1, 
2]. Hence, accurate assessment of BM infiltration forms an important part of 
lymphoma staging, and is conventionally based on BM aspirate (BMA) and trephine 
biopsy (BMB). However, BM infiltration can be heterogeneous and focal, so that 
sampling error might compromise the accuracy of BMA/BMB. Furthermore, 
BMA/BMB is an invasive procedure with potential complications [3, 4].  
 
In Hodgkin lymphoma (HL), recent evidence suggests that fused position emission 
tomography and computed tomography (PET/CT) could replace BMB [5]; whilst in 
aggressive non-Hodgkin lymphoma (NHL) of diffuse large B-cell subtype, a recent 
meta-analysis suggests that a positive PET/CT obviates the need of BMB [6]. 
However, there is currently insufficient evidence that the same can be applied in 
indolent NHL, largely due to the lower FDG avidity of indolent NHL, resulting in 
reduced sensitivity of PET/CT [7-9]. Furthermore, indolent NHL is a group of 
heterogeneous diseases with variable patterns of marrow infiltration on BMB, which 
may further confound the marrow activity on PET/CT [10, 11].  
 
PET/CT is increasingly used in the evaluation of indolent NHL, especially at 
detecting disease transformation, which may lead to treatment modification and 
disease prognostication [12-16].Several studies demonstrated moderate to high 
specificity (86-96%) of positive PET/CT marrow uptake in determining disease 
infiltration in different subtypes of indolent NHL, but these studies were limited by 
inclusion of relapsed patients whose marrow uptake might have been affected by 
previous intensive chemotherapy. There was also a lack of follow-up imaging to 
verify marrow uptake that was not concordant with BMB [17-19]. Finally, the 
correlation between marrow FDG uptake patterns and the histological evaluation with 
BMB remains unexplored. Herein, we aimed at evaluating the diagnostic accuracy of 






All consecutive staging PET/CT examinations with histological confirmed treatment-
naïve newly diagnosed indolent NHL from April 2007-March 2014 in one single 
centre were retrospectively reviewed. Patients with a history of previous radiation 
therapy, concurrent infection or recent granulocyte colony-stimulating factor (G-CSF) 
injections that might affect marrow uptake were excluded. The diagnosis of 
lymphoma was based on the 2008 WHO classification system [20] and grouped as 
indolent NHL based on the subtypes and clinical prognoses [21]. The local 
institutional research and ethics review board approved this retrospective study and 
waived the need for informed consent. 
 
Bone marrow assessment 
Bilateral BMA and BMB were performed in all patients. Morphological assessment, 
flow cytometric analysis, evaluation of percentage of lymphoid infiltration and 
immunohistochemical studies were performed, according to the 2008 WHO 
classification system [20]. For cases diagnosed prior to 2008, patients were 
retrospectively reviewed and reclassified. The pattern of marrow infiltration on 
trephine biopsy was evaluated as previously described [11, 22, 23]. These were 
classified as non-diffuse(focal non-paratrabecular, focal paratrabecular and 
intrasinusoidal) or diffuse (diffuse interstitial and diffuse solid). 
 
PET/CT  
All PET/CT examinations were acquired on a dedicated PET/CT scanner (Discovery 
VCT, 64-multislice CT, GE Healthcare Bio-Sciences Corp.). Patients were requested 
to fast 6 hours before PET/CT and serum glucose should not exceed 180mg/dl prior to 
injection of 10mCi (370MBq) 18F-fluoro-deoxyglucose (FDG). Acquisition of 
images was performed 60 minutes following FDG injection. For patients who had no 
prior diagnostic CT, the CT was performed with intravenous contrast medium using 
the following imaging parameters: field of view; 50 cm; pixel size, 3.91 mm; 120 
kVp; 200–400 mA; 0.5 s/CT rotation, pitch 0.984:1; 2.5 mm intervals; 1.5 mL/kg 
intravenous contrast medium injected at a rate of 2.0mL/second. Otherwise, low-dose 
CT was performed for attenuation correction with 80–200 mA and keeping other 
imaging parameters identical to the diagnostic CT acquisition. Each scan covered 
from the skull base to both the upper thighs. PET images were reconstructed using an 
ordered-subset expectation maximization iterative algorithm (14 subsets and two 
iterations), and CT was used for attenuation correction of the PET emission data. PET 
was analyzed on a dedicated PET/CT ADW4.3 workstation (GE Healthcare, 
Milwaukee, WI), with a consensus reached by two radiologists (EL and PL, 4 years 
and 7 years PET/CT experience respectively), who were blinded to the BMB results 
at the time of review. PET data presented in maximum intensity projection (MIP) was 
qualitatively evaluated and categorized into 3 patterns: (a)normal when BM metabolic 
uptake is lower than background liver metabolic uptake (PET/CT negative, –ve), (b) 
diffuse in the presence of generalized homogeneous marrow uptake equal or increased 
compared to liver (PET/CT positive, +ve), and (c) focal in the presence of localized 
region of increased FDG activity with or without corresponding CT osseous 
destruction or density change (PET/CT positive, +ve). CT features suggestive of 
benign or malignant osseous tumours were evaluated; these included systematically 
assessing the zone of transition, presence or absence of periosteal reaction and cortical 
destruction, and the underlying matrix and marrow density. Focal marrow uptake that 
corresponded to benign osseous lesion was excluded. The region of interest (ROI) 
was defined in areas with focal marrow uptake to quantify the pixel with the highest 
FDG uptake, normalized against lean body mass, giving the maximum standardized 
uptake value, denoted here as SUVBM. In the presence of multifocal uptake foci, the 
site with the highest uptake would be selected for quantification. In normal and 
diffuse PET/CT marrow uptake pattern, a standard sized ROI (1 cm3) was placed in 
4th lumbar vertebra body to quantify the SUVL4. The background liver uptake was 
taken as internal reference given its low intra-patient variability [24, 25]. The 
maximum FDG uptake in the liver was derived from placing a1 cm3 ROI in the centre 
of the right hepatic lobe (SUVliver). Metabolic ratio was defined as SUVL4/SUVliver. 
 
Standard of reference 
BMB was taken as standard of reference in PET/CT with normal or diffuse uptake 
pattern. In patient with focal uptake on PET/CT away from BMB sites and was 
discordant with BMB results, verification of focal uptake was based on serial 
PET/CT. True positive uptake was assumed when the lesion responded concordantly 
with the overall disease status following treatment, as evaluated with the Cheson’s 
criteria (complete response, partial response, stable disease or progressive disease) 
[26]; whereas marrow uptake discordant with the overall disease status on follow-up 
was taken as false positive osseous focus. 
 
Statistical analysis 
Clinical data and metabolic parameter were presented as mean and standard deviation 
(mean ±s.d.) with descriptive statistics. The diagnostic accuracy was evaluated by 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV). Mann-Whitney U test evaluated the difference in the metabolic ratio between 
PET/CT –ve and diffuse PET/CT +ve groups. Non-parametric Spearman’s rank 
correlation assessed the relationship between SUV and degree of lymphoid infiltration 
on BMA. All statistical analysis was performed using SPSS for Windows (version 20; 




The study population comprised 46patients (men:23; women:23) at 59±15 years old 
with indolent NHL (follicular lymphoma, n=11;lymphoplasmacytic lymphoma, n=12; 
mucosa-associated lymphoid tissue lymphoma, n=12; nodal marginal zone B-cell 
lymphoma, n=4; small lymphocytic lymphoma, n=1; low-grade B cell unclassifiable, 
n=6). None of the patients had histological evidence of large cell transformation, 
which would otherwise be treated as aggressive lymphoma. The interval between 
PET/CT and BMB was 4±9 days. 
 
PET/CT +ve with diffuse uptake pattern (n=15) 
All but one (14/15, 93%) cases had PET/CT findings concurring with BMB findings 
(SUVL4/ SUVliver 1.7±1.6; Fig. 1). One patient was PET/CT +ve but BMB was 
negative, resulting in one false positive. Twelve out of the 15 (80%) PET/CT +ve 
patients had diffuse marrow infiltration pattern and 2 (13%) patients had focal 
paratrabecular non-diffuse marrow infiltration pattern on BMB. Of note, 5 patients 
with diffuse marrow infiltration pattern also had concurrent non-diffuse pattern in 
sub-regions of the trephine samples. The lymphoid cells involvement ranged from 5-
90% (60 ± 27%, n=13). 
 
 
PET/CT +ve with focal uptake pattern (n=7) 
There was high concordance between focal uptake pattern on PET/CT with BMB (6/7, 
86%; Fig. 2). No predominant marrow infiltration pattern was identified with even 
distribution of diffuse (n=3) and non-diffuse (n=3) marrow patterns on BMB. The 
lymphoid cells involvement ranged from 38-69% (51 ± 16%, n=3). Only one patient 
had discordant finding with a uninvolved BMB, due to focal uptake in the right 
femur, corresponding to focal marrow hyperdensity on CT. Interim PET/CT 3 months 
later after 3 cycles of R-CHOP chemotherapy regimen demonstrated resolution of the 
right femoral activity, together with complete response in the other non-BM deposits 
(Fig. 3). Therefore, this case probably represented real marrow infiltration that was 
missed on BMB. The mean focal marrow uptake was SUVBM 3.8±1.2. 
 
PET/CT –ve (n=24) 
Twenty patients with normal marrow uptake (SUVL4/ SUVliver 0.8±0.2) concurred 
with negative BMB. The marrow metabolic ratio was significantly lower than 
PET/CT +ve group (p<0.001). There were 4 false negative (SUVL4/ SUVliver 0.7±0.1) 
cases from two follicular lymphoma, one low-grade B cell lymphoma and one small 
lymphocytic lymphoma. Two patients had concurrent diffuse and non-diffuse 
infiltration patterns on BMB whilst the other two patients had diffuse interstitial 
marrow infiltration pattern only. Three of these patients had moderate lymphoid cells 
involvement on BMA, ranging from 50-86% (72± 19%). 
 
Relationship between SUV and degree of lymphoid infiltration 
In our cohort, only 19 patients had positive BMA allowing for the evaluation of 
lymphoid infiltration degree. No statistical significant trend was observed between the 
marrow metabolic ratio and the degree of lymphoid infiltration (r=0.2, p=0.434). 
 
Diagnostic characteristics 
The overall accuracy of PET/CT in detecting BMI was 89% (41/46) with sensitivity 
of 84% (21/25), specificity of 95% (20/21), PPV 95% (21/22) and NPV 83% (20/24). 
In comparison, BMB has accuracy of 98% (45/46), sensitivity of 96% (24/25), 




The role of PET/CT in assessing marrow infiltration in indolent NHL is less well 
evaluated compared with aggressive NHL [6]. Our study showed that PET/CT was 
useful in diagnosing marrow infiltration given the high PPV and specificity, but was 
unable to replace BMB in view of the moderate sensitivity and NPV of PET/CT. Our 
study provided histopathological correlation in explaining the detectable FDG marrow 
avidity in indolent NHL, in that diffuse PET/CT uptake was associated with diffuse 
BMB pattern in 80% of the cases. However, the lack of significant correlation 
between metabolic ratio and degree of lymphoid infiltration suggested that the 
PET/CT uptake was not only dependent on the amount of lymphoid cells, but also the 
density of infiltration in terms of marrow infiltrative pattern on BMB. 
 
Indolent NHL is associated with higher incidence of marrow infiltration compared 
with aggressive lymphoma [27]. The marrow infiltration pattern is known to be 
related to histological subtypes. In particular, the paratrabecular pattern is more 
commonly associated with follicular lymphoma and less commonly with marginal 
zone B-cell lymphoma [11]. In our cohort, we observed an association between 
diffuse PET/CT marrow uptake and diffuse infiltration pattern on BMB. This finding 
would require further investigation in larger cohort to ascertain its significance. This 
is different in HL and aggressive NHL, where diffuse marrow uptake pattern could be 
attributed to inflammation and cytokine release [21, 28, 29]. This is especially true in 
HL where the microenvironment is dominated by extensive inflammatory cellular 
infiltrates with small fraction of tumour cells [30]. 
 
The advantage of PET/CT in detecting focal marrow disease was supported by our 
findings. PET/CT was more sensitive than BMB in one patient, where the iliac biopsy 
sites were non-FDG avid, likely illustrating the issue of sampling error with BMB [3, 
19]. Though no targeted biopsy was performed, we took care in verifying the 
discordant finding through analyzing the CT feature and the metabolic changes after 
chemotherapy [28]. Focal marrow uptake on PET/CT could potentially obviate BMB 
or even targeted re-biopsy of the sites with increased FDG avidity in indolent NHL, 
different to that suggested in aggressive NHL and HL that requiring re-examination of 
the FDG positive marrow sites [31].  
 
Concordant with others, a negative PET/CT could not replace BMB, because of the 
high false negative rate of 17% (4/24) and only a moderate sensitivity of 84% (21/25) 
[7-9, 32]. We propose that the relatively lower and heterogeneous FDG avidity in 
indolent NHL, and low density in marrow involvement could explain these discordant 
findings between BMB and PET/CT [8, 10]. 
The semi-quantitative analysis of the marrow uptake showed that significantly higher 
metabolic ratio was observed in the PET/CT +ve compared to PET/CT –ve groups, 
and the present findings are in line with two recent studies that showed added values 
of semi-quantitative evaluation over visual PET/CT analysis in marrow assessment 
[17, 19]. 
 
Our study was limited by the small number of patients with various histological 
subtypes of indolent-NHL that introduced study heterogeneity. However, we only 
included cases evaluated before treatment and excluded cases that could have 
metabolic marrow changes induced by non-lymphomatous factors, thus making the 
marrow evaluation more objective. None of the focal PET/CT marrow +ve lesions 
were biopsied to confirm histological infiltration, and the follow-up PET/CT was used 
as surrogate clinical marker in one discordant case. This could potentially introduce 
bias as inflammatory or benign bone lesion could be FDG avid. However, the CT 
feature and responsiveness following chemotherapy were supportive of 
lymphomatous involvement and consensus was reached through careful 
multidisciplinary discussion. Other marrow foci with focal uptake were concordant 
with BMB findings, so that it could be considered clinically unnecessary to re-biopsy 
these areas with focal activities given the lack of impact on clinical management. 
 
Conclusion 
PET/CT has high specificity and PPV in detecting marrow disease infiltration in 
indolent NHL, but is not sensitive enough to replace BMB. The metabolic uptake 
lacked significant correlation with degree of lymphoid infiltration but a potential 
relationship may exist between pattern of metabolic uptake and BMB infiltrative 
pattern.  Patients with definite PET/CT marrow +ve findings might not necessarily 
need a BMB, whereas patients with PET/CT -ve marrow findings will benefit from 
histological confirmation.  
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Table 1. Comparison of BM assessment based on BMB and PET/CT. NHL: non-
Hodgkin lymphoma; BMB: bone marrow biopsy; PET/CT: fused positron emission 
tomography and computed tomography; n: number; +ve: positive; -ve; negative; TP: 
true positive; TN: true negative; FP: false positive; FN: false negative. 
 
Fig.1. PET/CT of patient with low-grade B cell lymphoma showing diffuse PET/CT 
uptake in the marrow that was confirmed to be involved by BMB. 
(a) The MIP of PET/CT shows diffuse marrow uptake, visually more than the liver 
background activity (metabolic ratio, SUVL4/SUVliver 1.5). 
(b) Sagittal CT image shows no corresponding abnormality in the axial skeleton. 
MIP: maximum intensity projection; PET/CT: fused positron emission tomography 
and computed tomography; BMB: bone marrow biopsy. 
 
Fig.2. PET/CT of patient with follicular lymphoma showing multifocal osseous 
uptake on background of diffuse uptake; corresponding to positive iliac BMB. 
(a) Coronal PET image shows diffuse marrow uptake, visually more than the liver 
background activity (metabolic ratio, SUVL4/SUVliver 1.2). 
(b) Sagittal fused PET/CT image shows diffuse marrow uptake in the axial skeleton, 
in addition to conglomerate markedly hypermetabolic retroperitoneal nodal masses 
(up to SUVmax 8.9). 
(c) Axial fused PET/CT image shows focal marrow uptake at the right greater 
trochanter (white arrow, SUVBM 2.9). 
(d) Corresponding axial CT shows focal sclerosis at the right greater trochanter (white 
arrow).  
PET/CT: fused positron emission tomography and computed tomography; BMB: 
bone marrow biopsy; SUVmax: maximum standardized uptake value; SUVBM: 
maximum standardized uptake value of focal uptake. 
 
Fig. 3. PET/CT of patient with focal PET/CT uptake but negative iliac BMB. 
(a) The MIP of staging PET/CT shows extensive nodal disease involvement and 
multifocal marrow uptake affecting the axial and appendicular skeleton.  
(b) Coronal fused PET/CT image shows the most avid marrow lesion in the right 
proximal femur (SUVBM 5.0).  
(c) The MIP of interim PET/CT 3 months later after R-CHOP chemotherapy shows 
complete resolution of the hypermetabolic lymphadenopathy and marrow foci. 
(d) The corresponding coronal fused PET/CT image shows complete resolution of the 
right femoral uptake, concordant with the disease response elsewhere. 
MIP: maximum intensity projection; PET/CT: fused positron emission tomography 
and computed tomography; BMB: bone marrow biopsy; SUVBM: maximum 
standardized uptake value of focal uptake; R-CHOP: chemotherapy regime comprised 









TP TN FP FN Total 
PET/CT -ve        
Pattern: 
Normal 
4 20 0 20 0 4 24 
PET/CT +ve        
Pattern: 
Diffuse 
14 1 14 0 1 0 15 
Pattern: Focal 6 1 7 0 0 0 7 
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